Semaglutide in Youth With Autism Spectrum Disorder

NCT07770152 on ClinicalTrials.gov · last registry update 2026-08-18

Registered but not yet open, with 42 participants planned. Due to report 1 September 2028, alongside 23 other tracked readouts that quarter. Primary outcome, as filed: Number of Participants With Percent Change in BMI (kg/m2). Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: NOT_YET_RECRUITING
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Children's Hospital Medical Center, Cincinnati
Sponsor type: Other
Enrollment: 42
Started: 2026-09-01
Primary completion: 2028-09-01 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Number of Participants With Percent Change in BMI (kg/m2)

Conditions studied

Autism Spectrum Disorder · Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.